Shares of Edwards Lifesciences EW are bid lower in the after-hours following the release of the company's Q2 earnings results. Currently, shares are bid $81.27, at $82.00; they ended the regular session lower by 5.69%, at $82.55.
Edwards Lifesciences said that Q2 EPS came in at $0.49 on revenues of $431.2 million; the Street was looking for $0.50 per share on revenues of $425.4 million. Revenues increased 18.1% year over year.
"Growth outside the U.S. was particularly strong this quarter, including another impressive quarter for transcatheter heart valves," said Michael A. Mussallem, chairman and CEO.
"Our core heart valve and critical care product lines continued to perform well globally. And, we were pleased with the FDA advisory panel's recommendation for approval yesterday, which reinforces our confidence in a 2011 U.S. launch for the Edwards SAPIEN transcatheter heart valve."
Edwards Lifesciences Corporation is a global player in products and technologies designed to treat advanced cardiovascular disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in